医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Drug Discovery Unit (DDU), University of Dundee Licenses GVK BIO Online SAR Database (GOSTAR)

2013年04月10日 PM05:40
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

GVK Biosciences (GVK BIO) today announced that it has licensed its Online SAR Database – GOSTAR to the Drug Discovery Unit (DDU) at the University of Dundee. GOSTAR, a manually curated database, has been developed over the span of a decade by a team comprising of more than 200 curators. The product issued globally in various areas such as pharmaceuticals, academics, government sectors, apart from numerous publications that cite the data contained in GOSTAR. GOSTAR contains over 6 million compounds manually curated through the screening of over 2 million patents and 400,000 journals and it also contains more than 18 million quantitative SAR points.

GOSTAR is the final outcome after the integration of over fifteen individual databases, which includes the complete chemical space for ten of the popular Biological Targets. In addition to this, the MedChem Databases include all published and patented inhibitors against biological targets that exceed 6,500 in number. In addition to this, GOSTAR also contains two databases on Toxicity and Natural Products each. Several analysis tools have also been built into the product to enhance its performance.

Sreeni Devidas, Vice President Business Development at GVK BIO said, “We are excited that the Drug Discovery Unit (DDU) at the University of Dundee has decided to license GOSTAR. This database will provide valuable information to the researchers at Drug Discovery Unit (DDU) and aid them in their drug discovery endeavors.”

Professor Ian Gilbert, DDU Head of Medicinal Chemistry and Acting Head of the Division of Biological Chemistry said, “The Dundee Drug Discovery Unit (DDU) is pleased to be able to license the GOSTAR database from GVK BIO. The DDU has the remit of developing translational research at Dundee and outside, by bringing together the Unit’s experience of drug discovery in the pharma/biotech sector with basic academic research to identify new treatments for diseases. It is a rare fully operational and integrated drug discovery team within UK universities working across multiple disease areas, with the full range of disciplines required to produce novel hit and lead candidates. It is envisaged that the GOSTAR database will greatly impact the drug discovery efforts underway within the DDU.”

Informatics at GVK BIO

The Informatics division at GVK BIO is a frontrunner in the industry and is known for its manually curated databases in the area of SAR, Biomarkers and Clinical outcomes. In addition to this, the division also provides custom data curation services in multiple areas.

About GVK BIO

GVK Biosciences (GVK BIO) is Asia’s leading Discovery Research and Development organization. GVK BIO provides a broad spectrum of services, stand-alone and integrated, across the R&D value chain. Our discovery services consist of Chemistry, Biology and Informatics; the development services include Clinical Research, Clinical Pharmacology and Process R&D. GVK BIO’s diverse portfolio and prestigious clientele comprising of more than 150 customers includes some of the world’s largest pharmaceutical, biotechnology, agro, life-sciences companies and leading academic institutions. Please visit us at www.gvkbio.com to know more.

University of Dundee

The University of Dundee is internationally recognized for its excellence in life sciences and medical research. The University has a top-rated medical school engaged in intensive and expansive research from ‘the cell to the clinic to the community’, while the College of Life Sciences is home to some of the world’s most eminent scientists and more than 1000 research staff coming from 60 different countries.

CONTACT

GVK Biosciences Private Limited
Sreeni Devidas
Vice
President – Business Development
Columbia, MD 21045
001-443-838-6260
sreeni.devidas@gvkbio.com
www.gvkbio.com
or
Sushant
Datta

DGM – Corporate Brand & Communications
Hyderabad,
India
0091 40 66929999
sushant.datta@gvkbio.com
www.gvkbio.com

同じカテゴリーの記事 

  • 日本天皇陛下和皇后出席2024年度日本奖颁奖典礼
  • Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop® System Images Across Multiple Care Settings and Clinical Conditions
  • ReNAgade Therapeutics宣布在ASGCT第27届年会上发表演讲
  • ReNAgade TherapeuticsがASGCT第27回年次総会でのプレゼンテーションの内容を発表
  • BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer